Shafi Abu, Berry Alex J, Sumnall Harry, Wood David M, Tracy Derek K
East London Foundation Trust, London, UK.
Division of Psychiatry, University College London, UK.
Ther Adv Psychopharmacol. 2020 Dec 17;10:2045125320967197. doi: 10.1177/2045125320967197. eCollection 2020.
New psychoactive substances (NPS) are a heterogeneous group of substances. They are associated with a number of health and social harms on an individual and societal level. NPS toxicity and dependence syndromes are recognised in primary care, emergency departments, psychiatric inpatient and community care settings. One pragmatic classification system is to divide NPS into one of four groups: synthetic stimulants, synthetic cannabinoids, synthetic hallucinogens and synthetic depressants (which include synthetic opioids and benzodiazepines). We review these four classes of NPS, including their chemical structures, mechanism of action, modes of use, intended intoxicant effects, and their associated physical and mental health harms. The current challenges faced by laboratory testing for NPS are also explored, in the context of the diverse range of NPS currently available, rate of production and emergence of new substances, the different formulations, and methods of acquisition and distribution.
新型精神活性物质(NPS)是一类性质各异的物质。它们在个体和社会层面会造成一系列健康和社会危害。在初级保健、急诊科、精神科住院部及社区护理机构中,人们已认识到新型精神活性物质的毒性和依赖综合征。一种实用的分类系统是将新型精神活性物质分为以下四类之一:合成兴奋剂、合成大麻素、合成致幻剂和合成抑制剂(包括合成阿片类药物和苯二氮卓类药物)。我们将对这四类新型精神活性物质进行综述,包括它们的化学结构、作用机制、使用方式、预期的中毒效果以及与之相关的身心健康危害。同时,结合当前新型精神活性物质种类繁多、生产速度及新物质出现频率、不同配方以及获取和分销方式等情况,探讨实验室检测新型精神活性物质目前面临的挑战。